BioMedNewsBreaks Archive - Page 127 of 264

TuesdayJul 11, 2023 2:06 pm

BioMedNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Announces New Findings to Be Presented at Annual AAIC

INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced new findings from data to be presented at the annual Alzheimer’s Association International Conference (“AAIC”). Slated to take place in Amsterdam, Netherlands, AAIC is the largest medical meeting focused on Alzheimer’s disease (“AD”). “One of the difficulties in developing drugs for AD is the inability to quantify the disease and measure changes at the tissue or microstructure level. The current approaches to measure brain changes utilize imaging techniques that measure the whole brain,” said RJ Tesi,…

TuesdayJul 11, 2023 1:31 pm

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Expands C-Suite to Welcome Key GBB Drink Lab Execs

Jupiter Wellness (NASDAQ: JUPW), a diversified company that supports health and wellness, today announced that, along with the asset purchase agreement for the company’s purchased and provisional patents, two GBB Drink Lab executives will join Jupiter Wellness’ C-suite. Josh Wagner, the former U.S. director of sales for Anheuser Busch, where he led a $12 billion business with a 72 person sales team to their best performance since 2009, will serve as Jupiter Wellness’ chief revenue officer. In addition, David Sandler, the former COO and CSO of several supplement brands that exceeded $75 million in revenue, will serve as the company’s…

TuesdayJul 11, 2023 1:13 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in Bell2Bell Podcast

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, was featured in the latest episode of the Bell2Bell Podcast. The podcast is part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. BiondVax CEO Amir Reichman joined the program to discuss the company’s recent achievements. “At the end of 2022, we did a round of financing and raised about $8 million. We also started the negotiations to in-license the next antibody from the Max Planck Institute – namely the antibody for…

MondayJul 10, 2023 11:41 am

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Moves to Acquire ‘Safety Shot’ – the World’s First Rapid Blood Alcohol Detox Drink

Jupiter Wellness (NASDAQ: JUPW), a diversified company that supports health and wellness, today announced it has executed an asset purchase agreement with GBB Drink Lab Inc. Under the agreement, all operating assets related to GBB Drink Lab, including the revolutionary Safety Shot beverage, will belong to Jupiter Wellness. Safety Shot, which is protected by a number of issued and pending patents covering composition of matter and methods of use, creates a new product category for rapid alcohol detoxification in the fast-growing hangover remedy market. “The world-first breakthrough nature of Safety Shot and the market it addresses are a tremendous opportunity…

FridayJul 07, 2023 10:47 am

BioMedNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Secures $12M Line of Credit to Strengthen Efforts in Alzheimer’s Research

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, has secured a $12 million revolving line of credit from the Hong Kong Branch of O-Bank Co. Ltd. The funding will support IGC’s working capital needs primarily related to its Alzheimer’s research. Bradbury Asset Management (Hong Kong) Limited, a Hong Kong headquartered financial institution managing approximately $2 billion in assets, has collateralized cash assets in support of the line of credit. This follows the recent investment of $3 million in IGC led by four investment funds managed by Bradbury through a private placement, highlighting continued support for the company. “We are…

ThursdayJul 06, 2023 3:53 pm

BioMedNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Announces $3M Common Stock Private Placement

IGC Pharma (NYSE American: IGC), a company that develops advanced cannabinoid-based formulations for treating diseases and conditions, including but not limited to Alzheimer's disease, period cramps (dysmenorrhea), premenstrual syndrome ("PMS") and chronic pain, has received strategic investment support. According to an announcement from the company, it has received investments from four funds managed by Bradbury Asset Management (Hong Kong) Limited, a leading asset management firm with more than $2 billion in managed assets. The announcement also noted that additional contributions were received from three unrelated investors. In total, the company has received an estimated $3 million in gross proceeds. “The…

ThursdayJul 06, 2023 1:29 pm

BioMedNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Unique Treatment Paradigm Featured in Bell2Bell Podcast

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, was featured in the latest episode of Bell2Bell Podcast. The podcast is part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. Rodney Varner, GNPX’s chairman, president and CEO, and Ryan Confer, the company’s CFO, joined the program to discuss the journeys that led them to Genprex and the promise of the company’s drug development pipeline. “As I learned more and more about the technology, it became a passion of mine, as well,” said Confer. “What we’re…

WednesdayJul 05, 2023 1:53 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation in July’s Virtual Investor Summer Spotlight Series

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured in the Virtual Investor Summer Spotlight Series. Company CEO John Climaco and chief medical officer Sandra L. Silberman will both be participating on a live webcast scheduled for July 11, 2023, at 12 p.m. ET. The live event will be streamed on the company’s event’s page, and a replay of the webcast will be available later that day and will be accessible for 90 days, also on the company website. To…

MondayJul 03, 2023 11:31 am

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Well Positioned to Move next NanoAb Candidates into Clinical Application

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, recently signed an exclusive worldwide license agreement to develop and commercialize VHH antibodies (“NanoAbs”) that target Interleukin-17 (“IL-17”). “The license agreement is part of a broad-based collaboration with the Max Planck Society and the University Medical Center Göttingen (‘UMG’). The NanoAbs will be targeted toward the treatment of several relevant indications, including, but not limited to, psoriasis and psoriatic arthritis. BiondVax’s collaboration with the Max Planck Institute for Multidisciplinary Sciences and UMG, both based in Germany,…

FridayJun 30, 2023 1:50 pm

BioMedNewsBreaks – Panbela Therapeutics Inc. (NASDAQ: PBLA) Closes on Public Offering Totaling About $8.5M

Panbela Therapeutics (NASDAQ: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, has closed on its previously announced public offering. The offering consisted of 2,270,000 shares of its common stock or prefunded warrants in lieu thereof as well as two classes of warrants to purchase up to 4,540,000 shares of common stock (public warrants). The offerings were at a purchase price of $3.75 per share and associated public warrants and $3.749 per prefunded warrant and associated public warrants. According to the announcement, the prefunded warrants have an exercise price of $0.001 per…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Announces New Findings to Be Presented at Annual AAIC

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Expands C-Suite to Welcome Key GBB Drink Lab Execs

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in Bell2Bell Podcast

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Moves to Acquire ‘Safety Shot’ – the World’s First Rapid Blood Alcohol Detox Drink

BioMedNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Secures $12M Line of Credit to Strengthen Efforts in Alzheimer’s Research

BioMedNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Announces $3M Common Stock Private Placement

BioMedNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Unique Treatment Paradigm Featured in Bell2Bell Podcast

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation in July’s Virtual Investor Summer Spotlight Series

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Well Positioned to Move next NanoAb Candidates into Clinical Application

BioMedNewsBreaks – Panbela Therapeutics Inc. (NASDAQ: PBLA) Closes on Public Offering Totaling About $8.5M

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search